amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. the company is delivering its no compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. more information about the company is available at www.amyris.com.
Company profile
Ticker
AMRSQ, AMRSQ
Exchange
Website
CEO
John Melo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMYRIS BIOTECHNOLOGIES INC
SEC CIK
Corporate docs
Subsidiaries
Amyris Biotecnologia do Brasil Ltda. • Amyris Clean Beauty LATAM Ltda. • Amyris Fermentacao de Performance Ltda. • Amyris Purificacao de Performance do Brasil Ltda. • Interfaces Industria e Comercio de Cosmeticos Ltda. • AB Technologies LLC • Accessbio LLC • Amyris Clean Beauty, Inc. • Amyris Eco-Fab LLC • Amyris Fuels, LLC ...
AMRSQ stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
8 Apr 24
NT 10-K
Notice of late annual filing
2 Apr 24
8-K
Regulation FD Disclosure
28 Feb 24
EFFECT
Notice of effectiveness
22 Feb 24
EFFECT
Notice of effectiveness
22 Feb 24
EFFECT
Notice of effectiveness
22 Feb 24
EFFECT
Notice of effectiveness
22 Feb 24
EFFECT
Notice of effectiveness
22 Feb 24
EFFECT
Notice of effectiveness
22 Feb 24
EFFECT
Notice of effectiveness
22 Feb 24
Transcripts
AMRSQ
Earnings call transcript
2023 Q1
9 May 23
AMRSQ
Earnings call transcript
2022 Q4
15 Mar 23
AMRSQ
Earnings call transcript
2022 Q3
9 Nov 22
AMRSQ
Earnings call transcript
2022 Q2
9 Aug 22
AMRSQ
Earnings call transcript
2022 Q1
10 May 22
AMRSQ
Earnings call transcript
2021 Q4
1 Mar 22
AMRSQ
Earnings call transcript
2021 Q3
9 Nov 21
AMRSQ
Earnings call transcript
2021 Q2
5 Aug 21
AMRSQ
Earnings call transcript
2021 Q1
6 May 21
AMRSQ
Earnings call transcript
2020 Q4
2 Mar 21
Latest ownership filings
SC 13D/A
Foris Ventures, LLC
5 Jan 24
SC 13D/A
Foris Ventures, LLC
14 Dec 23
SC 13D/A
Foris Ventures, LLC
16 Oct 23
SC 13D/A
Foris Ventures, LLC
5 Oct 23
SC 13D/A
Foris Ventures, LLC
2 Oct 23
3
J. Scott White
20 Sep 23
SC 13D/A
Foris Ventures, LLC
20 Sep 23
3
Philip J. Gund
17 Aug 23
3
M. Freddie Reiss
17 Aug 23
SC 13D/A
Foris Ventures, LLC
10 Aug 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.45 mm | 17.45 mm | 17.45 mm | 17.45 mm | 17.45 mm | 17.45 mm |
Cash burn (monthly) | 17.72 mm | 22.94 mm | 67.55 mm | 55.50 mm | 30.00 mm | 38.62 mm |
Cash used (since last report) | 223.86 mm | 289.86 mm | 853.53 mm | 701.32 mm | 379.10 mm | 488.03 mm |
Cash remaining | -206.41 mm | -272.41 mm | -836.08 mm | -683.87 mm | -361.65 mm | -470.58 mm |
Runway (months of cash) | -11.7 | -11.9 | -12.4 | -12.3 | -12.1 | -12.2 |
Institutional ownership, Q3 2023
7.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 3 |
Closed positions | 21 |
Increased positions | 0 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 39.51 bn |
Total shares | 28.81 mm |
Total puts | 4.00 |
Total calls | 56.00 |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Venrock Healthcare Capital Partners III | 7.98 mm | $3.04 mm |
BCLS II Equity Opportunities | 5.35 mm | $0.00 |
EcoR1 Capital Fund Qualified | 5.00 mm | $2.28 mm |
Integrated Core Strategies | 3.13 mm | $0.00 |
Lilly Ventures Fund I | 2.57 mm | $20.21 mm |
LLY Lilly(Eli) & Co | 1.53 mm | $7.25 mm |
Driehaus Capital Management | 800.85 k | $9.81 bn |
Fairmount Funds Management | 378.42 k | $4.64 bn |
Polar Capital | 300.00 k | $3.68 bn |
Wellington Management | 299.93 k | $3.67 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Jun 23 | Doerr L John | 2019 LSA Common Stock | Grant | Acquire A | Yes | No | 3 | - | 63.01 mm | - |
5 Jun 23 | Doerr L John | 2019 LSA Common Stock | Sale back to company | Dispose D | Yes | No | 3 | - | 63.01 mm | 0 |
2 Jun 23 | Kieftenbeld Hermanus | Common Stock | Sell | Dispose S | No | No | 0.95 | 3,500 | 3.33 k | 219,768 |
2 Jun 23 | Kieftenbeld Hermanus | Common Stock | Sell | Dispose S | No | No | 0.95 | 17,499 | 16.62 k | 223,268 |